Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNOC029 Tovorafenib for Craniopharyngioma in Children and Young Adults
2024-511510-20-00Phase 2Authorised
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of tovorafenib in craniopharyngioma (3 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: PFS12 and QOL12. Planned start Mar 2026; status: authorised.
02
Drugs
tovorafenib
03
Conditions
craniopharyngioma
Beyond the preview
Go deeper on 2024-511510-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511510-20-00.